Durvalumab for BCG-Unresponsive Urothelial Carcinoma In Situ of the Bladder
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
Clin. Cancer Res 2023 Jul 28;[EPub Ahead of Print], R Li, WJ Sexton, J Dhillon, A Berglund, S Naidu, G Borjas, K Rose, Y Kim, X Wang, JR Conejo-Garcia, RK Jain, MA Poch, PE Spiess, J Pow-Sang, SM Gilbert, J ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.